ALXN News and Press, Alexion Pharmaceuticals Inc. From 01/30/20

Image source: The Motley Fool. Alexion Pharmaceuticals Inc   (NASDAQ: ALXN) Q4 2019 Earnings Call Jan 30, 2020 , 7:30 a.m. ET Operator Continue reading

As fears of a global pandemic continue to grip stock markets and crude oil, not even the biotechnology sector ( IBB ) could escape the wrath with IBB declining more than 6% from year-to-date highs. Indeed, although a handful of biotech names such as VIR which are developing vaccines for the...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Alexion Pharmaceuticals ( ALXN ) Q4 results: Revenues: $1,384.3M (+22.6%); Soliris: $1,013.1M (+3.7%); Ultomiris: $170.2M; Strensiq: $166.8M (+32.3%); Kanuma: $34.1M (+32.7%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the m...

When looking at biotech stocks, a big point of focus should be on the products driving revenue now or the solidity of the pipeline, which will drive revenue later. Acadia Pharmaceuticals (NASDAQ: ACAD) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Seattle Genetics (NASDAQ: SGEN) are ...

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 Non-GAAP EPS of $2.71 beats by $0.10 ; GAAP EPS of $4.00 beats by $1.91 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71 Received Japanese approval for SOLIRIS ® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD) Established ULTOMIRIS ® (r...

– Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition ...

Agile Therapeutics, Inc. (AGRX) is drawing close to an important milestone as the PDUFA date for its Twirla drug candidate is now right around the corner. The Food and Drug Administration is scheduled to announce its decision on February 16 th . The FDA was earlier supposed to pass the verdict...

Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...